Otsuka Pharmaceutical Company, Limited

Yasufumi Uwahodo

Tetsuro Kikuchi

Tsuyoshi Hirose

Katsura Tottori

Shaun Jordan

Shaun Jordon

The present invention relates to a method of treating a patient suffering from a disorder of the central nervous system associated with 5-HTreceptor subtype, comprising as an active ingredient a carbostyril derivative or a salt thereof represented by the formula (1): wherein the carbon-carbon bond between 3- and 4-positions in the carbostyril skeleton is a single or a double bond.

5-HT1A receptor subtype agonist

The present invention relates to a method of treating a patient suffering from a disorder of the central nervous system associated with 5-HTreceptor subtype, comprising as an active ingredient a carbostyril derivative or a salt thereof represented by the formula (1) wherein the carbon-carbon bond between 3- and 4-positions in the carbostyril skeleton is a single or a double bond.

Method of treating cognitive impairments and schizophrenias

[object Object]

Method of treating neurodegenerative diseases

Method of treating down's syndrome

Method of treating autism

Method of treating panic disorder

Method of treating Attention Deficit Hyper-Activity Disorder

The present invention relates to a method of treating a patient suffering from a disorder of the central nervous system associated with 5-HTreceptor subtype, comprising as an active ingredient a carbostyril derivative or a salt thereof represented by the formula (1):wherein the carbon-carbon bond between 3- and 4-positions in the carbostyril skeleton is a single or a double bond.

5-HT1a receptor subtype agonist

Growing community of inventors

Tokushima, Japan

Yasufumi Uwahodo